The WTO estimates that in 2010 there were 219 million cases of malaria for malaria in 660,000 deaths [48]. Chemotherapeutic tools are attractive for malaria elimination, as there is no vaccine that is commercially available. Primaquine has a vital and unique role in the malaria elimination toolkit. First, primaquine is the only drug active against mature , infectious P.falciparum gametocyte making it vital for blocking transmission. It is the only licensed radical cure od P.vivax . Finally , in areas of emerging drug resistance , primaquine is being used in containment programs to prevent the spread of artemisinin resistant P.falciparum strain [3,49] . However , primaqiune treatment causes hemolytic anemia in g6pd- deficient individual [50-52] a major drawback for its application in malaria elimination campaigns. The mechanism by which primaquine - induced hemolysis occurs remain